Some previous studies have reported that IL6 may participate in the pathogenesis of rheumatoid arthritis (RA), and several clinical trials have been carried out evaluating safety and efficacy of Tocilizumab—an anti-IL6 antibody—in RA patients [28]. Here, IL6 is linked to rheumatoid arthritis.